Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Allogene Therapeutics, Inc. - Common Stock
(NQ:
ALLO
)
2.110
+0.030 (+1.44%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
March 01, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
February 21, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
5 Analysts Have This to Say About Allogene Therapeutics
↗
January 24, 2023
Via
Benzinga
Expert Ratings for Allogene Therapeutics
↗
January 06, 2023
Via
Benzinga
Short Squeezes Have Returned in 2023 -- Here's Your Playbook
↗
February 08, 2023
We haven't seen moves like these in a couple of years, so here's what investors should know.
Via
The Motley Fool
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
February 01, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
January 25, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Why Allogene Therapeutics Shares Are Seeing Blue Skies Today
↗
January 24, 2023
Allogene Therapeutics Inc (NASDAQ: ALLO) shares are trading higher by 13.1% to $7.76 Tuesday morning after the company announced data from its Phase 1 UNIVERSAL trial of ALLO-715 has been published in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
↗
January 24, 2023
Via
Benzinga
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
January 24, 2023
ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple Myeloma
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Amazon To Rally Over 28%? Here Are 10 Other Analyst Forecasts For Tuesday
↗
January 24, 2023
Citigroup raised the price target for AT&T Inc. (NYSE: T) from $20 to $22. Citigroup analyst Michael Rollins maintained a Buy rating. AT&T shares fell 1% to $18.91 in pre-market trading.
Via
Benzinga
Yext, 1-800-Flowers.com And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
↗
January 24, 2023
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
January 17, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
WWE, AMTD Digital And Some Other Big Stocks Moving Higher In Friday's Pre-Market Session
↗
January 06, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. AMTD Digital Inc. (NYSE: HKD) shares surged 118.8% to $65.54 in pre-market...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
↗
January 06, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
↗
January 05, 2023
On Thursday, 63 companies set new 52-week lows.
Via
Benzinga
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
↗
January 05, 2023
Via
Benzinga
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
January 03, 2023
Cell Therapy Veteran and Former Kite Pharma Clinical Leader to Head Development of Expanding Portfolio of Allogeneic CAR T Product Candidates
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
↗
December 22, 2022
Crispr and Vertex are working toward the first submissions for a CRISPR-based product.
Via
Investor's Business Daily
Top 10 Highest Short Interest Stocks And 10 With Highest Cost To Borrow: Where Do Carvana, MicroStrategy, Fisker And AMC Rank?
↗
December 17, 2022
Investors often look for stocks with high short interest and a high cost to borrow, which could predict a potential short squeeze. New data shared by S3 Partners could signal which stocks investors are...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
December 23, 2022
OnFriday, 143 stocks hit new 52-week lows.
Via
Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
↗
December 12, 2022
U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
↗
December 12, 2022
Via
Benzinga
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
↗
December 08, 2022
-Clinical Data Due Next Week at ASH-
Via
Benzinga
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
November 29, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
November 10, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
November 09, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
November 03, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
